Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

Dose Response Pharmacogenetic Study of ADHD

Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted.

Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response

Inclusion Criteria:

• 6-17 DSM IV criteria for ADHD Parents willing to complete measures

Exclusion Criteria:

• Mental retardation psychoses seizure disorder